DIRS.INFO The most relevant business & tech news

☆ Amplify rolls out first SOFR-based ETF for income seekers
▼ + stars: | 2023-11-15 | by ( Suzanne Mcgee | ) www.reuters.com time to read: +2 min

The Amplify Samsung SOFR ETF , which debuted Wednesday, is the first ETF to track SOFR, the overnight interbank lending rate that has emerged as the U.S. replacement for the now-defunct Libor gauge of overnight borrowing interest costs. The new fund's launch comes amidst a wave of enthusiasm for ultra-short term fixed income ETFs, as yields on products throughout the fixed income spectrum have risen to multi-year highs following an aggressive rate hiking cycle by the Federal Reserve. "It wasn't until this year that rate-driven products became priorities," said Bill Belden, president of Amplify. Flows into money market and ultra-short term products account for about 36% of all inflows into fixed income ETFs this year, though the category represents only 15% of all fixed income ETF assets, according to Matthew Bartolini, head of product research at State Street Global's SPDR Americas ETF division. Belden said that a large institutional investor has provided seed capital of $50 million for the new ETF.

Persons: Yves Herman, Bill Belden, Matthew Bartolini, SOFR, Belden, Suzanne McGee, Ira Iosebashvili, Cynthia Osterman Organizations: Samsung, REUTERS, ETF, Federal Reserve, Thomson Locations: Brussels, Diegem, Belgium, U.S, Americas

☆ J&J says DoJ seeking information related to eye products in civil investigation
▼ + stars: | 2023-10-27 | by ( ) www.reuters.com time to read: 1 min

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. REUTERS/Yves Herman/File Photo Acquire Licensing RightsOct 27 (Reuters) - Johnson & Johnson (JNJ.N) disclosed on Friday that the U.S. Department of Justice (DOJ) in July had sought documents and information related to the drugmaker's free and discounted eye surgery products in connection with a civil investigation. The company said it had begun complying with the DoJ's civil investigative demands. J&J said it is in ongoing discussion with DOJ regarding the inquiry. Reporting by Khushi Mandowara in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Persons: Johnson, Yves Herman, J, Khushi, Shailesh Organizations: Johnson, REUTERS, U.S . Department of Justice, Thomson Locations: Brussels, Diegem, Belgium, Bengaluru

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. J&J raised its annual profit forecast, helped by strong sales from its pharmaceutical business, and shares of the U.S. healthcare conglomerate were off about 1%. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, up from its previous view of $10.00 to $10.10. Sales at J&J's medical device unit came in at $7.46 billion, shy of Wall Street estimates of $7.58 billion. J&J finalized the biggest shake-up in its 137-year history in August with the spinoff, but retained a 9.5% stake in its iconic consumer health business.

Persons: Johnson, Yves Herman, J, Vamil Divan, Joseph Wolk, Ozempic, Wolk, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta, Bill Berkrot Organizations: Johnson, REUTERS, Guggenheim Partners, Vamil, Reuters Graphics, J, Thomson, &' $, & $, & $ Locations: Brussels, Diegem, Belgium, Bengaluru, New York

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57 billion in drug sales by 2025. Johnson & Johnson recorded a $21-billion gain in the third quarter from the spin-off of its consumer health unit. Stelara, J&J's top-selling anti-inflammatory drug, brought in sales of $2.86 billion in the quarter, above LSEG estimates of $2.61 billion. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.

Persons: Johnson, Yves Herman, MedTech, Cantor Fitzgerald, Louise Chen, Stelara, Joseph Wolk, Wolk, J, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta Organizations: Johnson, REUTERS, Innovative Medicine, Reuters, Thomson, & $, & $ Locations: Brussels, Diegem, Belgium, Stelara, U.S, United States, Bengaluru, New York

Samsung shares opened 3.3% higher versus a 1.4% rise in the wider market (.KS11), as analysts said memory chip prices likely bottomed in the third quarter, with some types starting to rebound. The world's largest memory chip and smartphone maker estimated its operating profit fell to 2.4 trillion won ($1.79 billion) in July-September, from 10.85 trillion won a year earlier in a short preliminary earnings statement. The profit beat a 2.1 trillion won LSEG SmartEstimate, which is weighted toward forecasts from analysts who are more consistently accurate. The company reported losses of 4.58 trillion won and 4.36 trillion in its chip business in the first and second quarter respectively, as memory chip prices plunged and its inventory values were slashed. Samsung's said its revenue likely fell 13% from the same period a year earlier to 67 trillion won.

Persons: Yves Herman, LSEG, Ko Yeongmin, chipmakers, Ko, Samsung's, 1,342.1900, Joyce Lee, Heekyong Yang, Jamie Freed Organizations: Samsung, REUTERS, Samsung Electronics, Daol Investment, Securities, Apple, Thomson Locations: Brussels, Diegem, Belgium, SEOUL

The world's largest memory chip and smartphone maker estimated its operating profit fell to 2.4 trillion won ($1.79 billion) in July-September, from 10.85 trillion won a year earlier in a short preliminary earnings statement. The profit beat a 2.1 trillion won LSEG SmartEstimate, which is weighted toward forecasts from analysts who are more consistently accurate. Although down sharply from last year, Samsung's third quarter profit is higher than the first quarter's 640 billion won and the second quarter's 670 billion won. Rival Micron Technology (MU.O) also forecast a quarterly loss last month, triggering concerns of a sluggish recovery in the memory chip maker's end markets such as data centres. Samsung's revenue likely fell 13% from the same period a year earlier to 67 trillion won, Samsung said in the statement.

Persons: Yves Herman, LSEG, Samsung's, chipmakers, 1,342.1900, Joyce Lee, Heekyong Yang, Jamie Freed Organizations: Samsung, REUTERS, Rights, Samsung Electronics Co, Micron Technology, Apple, Thomson Locations: Brussels, Diegem, Belgium, Rights SEOUL, KS, Korean

☆ Samsung to manufacture chips from AI chip startup Tenstorrent
▼ + stars: | 2023-10-02 | by ( Max A. Cherney | ) www.reuters.com time to read: +2 min

REUTERS/Yves Herman/File Photo Acquire Licensing RightsOct 2 (Reuters) - Samsung's contract chip manufacturing arm picked up a new artificial intelligence chip customer, a Canadian startup called Tenstorrent, the company said on Monday. Tenstorrent is among a number of startups looking to challenge Nvidia (NVDA.O), which dominates the market for AI chips. As part of the deal, Tenstorrent plans to use one of Samsung's advanced manufacturing processes, known as 4nm, to produce the chips. The chip Samsung will manufacture is named Quasar, and is not based on RISC-V technology. The chip deal follows a Samsung investment in Tenstorrent in August as part of a $100 million capital raise that included Hyundai Motor Co (005380.KS) and others.

Persons: Yves Herman, Tenstorrent, Jim Keller, Max A, Leslie Adler Organizations: Samsung, REUTERS, Nvidia, Intel, Micron Devices, Hyundai Motor Locations: Brussels, Diegem, Belgium, Canadian, Tenstorrent, San Francisco

☆ Aid agency urges Johnson & Johnson to improve access to tuberculosis drug
▼ + stars: | 2023-09-30 | by ( ) www.reuters.com time to read: +2 min

FILE PHOTO:The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. REUTERS/Yves Herman/File Photo Acquire Licensing RightsGENEVA, Sept 29 (Reuters) - Global health aid agency Unitaid has written to Johnson & Johnson's (JNJ.N) CEO, Joaquin Duato, urging "immediate action" to expand access to the company's tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives. The agency is urging J&J to remove all secondary patents and ensure that lower prices are available to all countries with high TB cases. TB, a bacterial disease that mostly affects the lungs, is preventable and treatable, but 10 million people catch it annually. Around 1.6 million people died from TB in 2021, almost entirely in low- and middle-income countries, according to the World Health Organization (WHO).

Persons: Johnson, Yves Herman, Unitaid, Joaquin Duato, Philippe Duneton, J, Emma Farge, Jennifer Rigby, Devika Nair, Susan Fenton, Elaine Hardcastle, Leslie Adler Organizations: Johnson, REUTERS, Rights, UN, Assembly, World Health Organization, WHO, Thomson Locations: Brussels, Diegem, Belgium, South Africa, Belarus, Ukraine

The logo of accounting firm PricewaterhouseCoopers (PwC) is seen on the top of a Brussels' office of the company, in Diegem, Belgium September 21, 2023. REUTERS/Yves Herman Acquire Licensing RightsSYDNEY, Sept 27 (Reuters) - PwC Australia will appoint outsiders to its board and publish audited financial statements as part of a governance overhaul to bring the partnership closer to public company standards following a scandal over the leak of confidential tax documents. PwC Australia will announce plans on Wednesday to apply some Australian Stock Exchange governance principles including appointing two non-executive directors and a non-executive chair to its board, according to excerpts of plans provided by PwC. The changes form part of PwC Australia's response to a months-long independent review into its governance and culture, which will be published in full on Wednesday. Australia said last month it would drastically toughen penalties against those who promote dodgy tax schemes and strengthen regulators in response to the scandal.

Persons: Yves Herman Acquire, Kevin Burrowes, Ziggy Switkowski, Lewis Jackson, Kim Coghill Organizations: PricewaterhouseCoopers, REUTERS, Rights, Facebook, Australian Stock Exchange, PwC, “, Telstra, Thomson Locations: Brussels, Diegem, Belgium, Australia

Search resuls for: "Diegem"

9 mentions found